Structural Bioinformatics has named Ian McDonald vice president of drug discovery, where he will be directly responsible for all aspects of SBI’s drug discovery efforts.
McDonald’s prior post was senior director of chemistry at Merck Research Laboratories. He has published about 80 peer-reviewed papers and book chapters and is an inventor on 32 US issued patents.
Christopher Hogue will serve MDS Proteomics as chief information officer. He will lead the company’s bioinformatics efforts. Hogue was formerly a scientist at the Samuel Lunenfeld Research Institute and an assistant professor in the department of biochemistry at the University of Toronto.
MDS also named Caroline Popper as chief business officer. Both Popper and Hogue report directly to president and CEO Frank Gleeson.
EraGen Biosciences has elected David O’Bryan, former vice president and director of science and technology at SmithKline Beecham Clinical Laboratories, to serve on its Board of Directors. O’Bryan is currently managing director of Hibernia Consulting Partners, serves as a member of Bayer Diagnostic’s Strategic Advisory Board, and is a member of the NCCLS Area Committee on Laboratory Automation.
Tanox, a developer of therapeutic monoclonal antibodies, has tapped Bing Yao to head its newly established Genomics/Bioinformatics Group. Yao was previously head of CNS molecular biology and genomics at Aventis Pharmaceuticals, where he was responsible for target discovery.